SELLAS Reports Survival Benefit in Phase 3 Leukemia Trial
SELLAS Life Sciences said its Phase 3 REGAL trial of the experimental cancer vaccine galinpepimut-S met its primary overall-survival endpoint in patients with acute myeloid leukemia, reporting median survival of 24 months with the vaccine compared with 14.7 months with investigator-selected treatment. Shares rose sharply after the announcement on Tuesday, November 17, at one point gaining more than 200% during trading, according to reports.
The company reported a hazard ratio of 0.59, corresponding to a 41% lower risk of death for patients receiving GPS, and a two-sided p-value of 0.035. The final analysis followed 80 deaths, in line with the trial plan. These are company-reported topline findings; full trial data have not yet been presented or peer reviewed.
REGAL studied adults whose leukemia had reached a second or later remission but who could not undergo a stem-cell transplant. GPS was given as maintenance therapy. The comparison group received care selected by their doctors, which could include observation or specified medicines, rather than one fixed treatment regimen. The trial registry lists 127 participants, while company-results accounts describe 126; the reports do...